Continuous glucose monitor (CGM) use in diabetes is associated with improved clinical outcomes. However, evidence is lacking on whether changes in outcomes differ by CGM type. We compared clinical events between FreeStyle Libre and Dexcom recipients.
We conducted a retrospective study using IBM MarketScan™ Commercial Claims and Medicare Supplemental data on adults (18+ years) with a non-gestational T1D or T2D ICD-10 diagnosis, on rapid-/short-acting insulin (T2D), CGM naïve, ≥ 6 months pre-CGM data, and FreeStyle Libre /FreeStyle Libre 14 Day or Dexcom G5/G6 system purchase between Q4 2017 - Q2 2019. After propensity score matching on demographics (age, gender, geography), provider visits, comorbidities, insulin pump, and baseline events, we assessed 6-month acute diabetes events (hyper-/hypoglycemia emergency visits/hospitalizations) and all-cause hospitalization (ACH). Separate analyses were conducted for T1D and T2D. In matched T1D (N=3564) and T2D (N=3930) cohorts, there were no significant differences between FreeStyle Libre and Dexcom in post-CGM diabetes events (Figure). ACH-free survival ranged from 90.4-95.4%, with no significant differences between CGMs. This real-world study of FreeStyle Libre and Dexcom recipients did not find differences in clinical outcomes between CGM types.
I. B. Hirsch: Consultant; Self; Abbott Diabetes, Bigfoot Biomedical, Inc., Research Support; Self; Insulet Corporation, Leona M. and Harry B. Helmsley Charitable Trust, Medtronic. G. J. Roberts: Employee; Self; Abbott. J. Joseph: Employee; Self; Abbott. Y. Nabutovsky: Employee; Self; Abbott, Stock/Shareholder; Self; Abbott. N. Virdi: Employee; Self; Abbott Diabetes, Stock/Shareholder; Self; Johnson & Johnson. E. Miller: Advisory Panel; Self; Abbott Diabetes, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk Inc., Research Support; Self; Pendulum Therapeutics, Research Support; Spouse/Partner; Abbott Diabetes.